Medicover Gestion

Gestion contrôle des critères 3/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Fredrik Rågmark

Directeur général

€2.7m

Rémunération totale

Pourcentage du salaire du PDG	39.2%
Durée du mandat du directeur général	27.8yrs
Propriété du PDG	1.0%
Durée moyenne d'occupation des postes de direction	3.4yrs
Durée moyenne du mandat des membres du conseil d'administration	15.3yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Fredrik Rågmark a-t-elle évolué par rapport aux bénéfices de Medicover?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	€20m
Jun 30 2024	n/a	n/a	€23m
Mar 31 2024	n/a	n/a	€22m
Dec 31 2023	€3m	€1m	€18m
Sep 30 2023	n/a	n/a	€8m
Jun 30 2023	n/a	n/a	€5m
Mar 31 2023	n/a	n/a	€1m
Dec 31 2022	€3m	€1m	€12m
Sep 30 2022	n/a	n/a	€37m
Jun 30 2022	n/a	n/a	€59m
Mar 31 2022	n/a	n/a	€88m
Dec 31 2021	€2m	€952k	€102m
Sep 30 2021	n/a	n/a	€93m
Jun 30 2021	n/a	n/a	€90m
Mar 31 2021	n/a	n/a	€52m
Dec 31 2020	€2m	€670k	€26m
Sep 30 2020	n/a	n/a	€14m
Jun 30 2020	n/a	n/a	€4m
Mar 31 2020	n/a	n/a	€16m
Dec 31 2019	€1m	€900k	€23m
Sep 30 2019	n/a	n/a	€19m
Jun 30 2019	n/a	n/a	€19m
Mar 31 2019	n/a	n/a	€20m
Dec 31 2018	€1m	€807k	€22m
Sep 30 2018	n/a	n/a	€28m
Jun 30 2018	n/a	n/a	€26m
Mar 31 2018	n/a	n/a	€23m
Dec 31 2017	€921k	€810k	€19m

Rémunération vs marché: La rémunération totale de Fredrik ($USD 2.85M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché UK ($USD 2.07M ).

Rémunération et revenus: La rémunération de Fredrik a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.

PDG

Fredrik Rågmark (61 yo)

27.8yrs

Titularisation

€2,707,000

Compensation

Mr. Fredrik Ragmark serves as the Chief Executive Officer of Medicover AB (publ). Mr. Ragmark has been employed with Medicover since 1996. He serves as Managing Director and Board Member of Kalvskär AB.Fr...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Fredrik Rågmark	CEO & Director	no data	€2.71m	1.04% SEK 272.5m
Anand Patel	Chief Financial Officer	less than a year	pas de données	pas de données
Jaroslaw Urbanczyk	Chief Information Officer	5.1yrs	pas de données	0.0052% SEK 1.3m
Hanna Bjellquist	Head of Investor Relations	no data	pas de données	pas de données
Jenny Brandt	General Legal Counsel	no data	pas de données	0.031% SEK 8.1m
Andrew Vallance-Owen	Chief Marketing Officer	no data	pas de données	pas de données
Kamila Skorupinski	Group Chief People Officer	less than a year	pas de données	pas de données
John Stubbington	Chief Operating Officer of Healthcare Services	8.8yrs	pas de données	0.53% SEK 138.4m
Staffan Ternstrom	Chief Operating Officer for Diagnostic Services	3.4yrs	pas de données	0.035% SEK 9.2m

3.4yrs

Durée moyenne de l'emploi

57.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de 0RPS est considérée comme expérimentée (ancienneté moyenne 3.4 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Fredrik Rågmark	CEO & Director	27.8yrs	€2.71m	1.04% SEK 272.5m
Robert Jochnick	Independent Director	17.8yrs	€54.60k	1.21% SEK 317.0m
Fredrik Stenmo	Independent Chairman	19.8yrs	€101.50k	4.41% SEK 1.2b
Margareta Nordenvall	Independent Director	23.8yrs	€66.20k	0.060% SEK 15.7m
Arno Bohn	Independent Director	23.8yrs	€63.05k	0.20% SEK 52.3m
Cecil Michael Flemming	Independent Director	9.8yrs	€78.30k	pas de données
Anne Berner	Independent Director	2.6yrs	€59.85k	pas de données
Azita Shariati	Independent Director	2.6yrs	€63.05k	0.0015% SEK 384.5k
Peder Jochnick	Independent Director	12.8yrs	€54.60k	2.59% SEK 676.7m
Sonali Chandmal	Independent Director	7.8yrs	€71.45k	0.017% SEK 4.4m

15.3yrs

Durée moyenne de l'emploi

60.5yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la 0RPS est chevronné et expérimenté ( 15.3 années d'ancienneté moyenne).

Medicover Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Insider recently bought kr498k worth of stock

Medicover AB (publ) Announces Nomination Committee for the AGM 2025

Medicover AB (publ), Annual General Meeting, Apr 25, 2025

Medicover AB (publ) Appoints Anand Patel as Chief Financial Officer, Effective October 1, 2024

General Legal Counsel recently sold kr1.2m worth of stock

Insider recently bought kr1.8m worth of stock

Recent updates

Insider recently bought kr498k worth of stock

Third quarter 2024 earnings released: €0.029 loss per share (vs €0.007 loss in 3Q 2023)

Medicover AB (publ) to Report First Half, 2025 Results on Jul 24, 2025

Medicover AB (publ) Announces Nomination Committee for the AGM 2025

Medicover AB (publ), Annual General Meeting, Apr 25, 2025

Medicover AB (publ) Appoints Anand Patel as Chief Financial Officer, Effective October 1, 2024

Second quarter 2024 earnings released: EPS: €0.042 (vs €0.037 in 2Q 2023)

Medicover AB (Publ) Provides Revenue Guidance for Year-End 2025

General Legal Counsel recently sold kr1.2m worth of stock

Medicover AB (Publ) Provides Revenue Guidance for Year-End 2025

First quarter 2024 earnings released: EPS: €0.041 (vs €0.01 in 1Q 2023)

Upcoming dividend of €0.12 per share

New minor risk - Earnings quality

Full year 2023 earnings released: EPS: €0.12 (vs €0.079 in FY 2022)

Dividend of €0.12 announced

Insider recently bought kr1.8m worth of stock

Full year 2023 earnings released: EPS: €0.12 (vs €0.081 in FY 2022)

Now 22% undervalued

Medicover AB (publ) Provides Earnings Guidance for the Financial Year 2025

Medicover Appoints Kamila Skorupinski as Chief People Officer as of 1 April 2024

Independent Chairman recently bought kr3.9m worth of stock

Medicover AB (Publ) Provides Revenue Targets for by Year-End 2025

Medicover AB (Publ) Provides Revenue Targets for by Year-End 2025

Third quarter 2023 earnings released

Medicover AB (Publ) Announces Resignation of Joe Ryan as Chief Financial Officer

Independent Director recently bought kr303k worth of stock

Medicover AB (publ) Announces Nomination Committee for the Annual General Meeting 2024

Medicover AB (publ), Annual General Meeting, Apr 26, 2024

Independent Director recently bought kr1.4m worth of stock

Independent Chairman recently bought kr6.3m worth of stock

Second quarter 2023 earnings released: EPS: €0.037 (vs €0.01 in 2Q 2022)

Medicover AB (publ) to Report Q1, 2024 Results on Apr 26, 2024

Insider recently bought kr242k worth of stock

Chief Information Officer recently bought kr321k worth of stock

Upcoming dividend of €0.12 per share at 0.7% yield

Full year 2022 earnings released

Now 24% undervalued

Full year 2022 earnings released

Medicover AB (publ) Proposes Dividend for 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings released

Medicover AB (publ) to Report Q2, 2023 Results on Jul 26, 2023

Medicover AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

Medicover AB (publ) (OM:MCOV B) acquired Übag Mvz Meindentist Gbr.

Medicover AB (publ) (OM:MCOV B) completed the acquisition of Laurus Medical SRL.

Medicover AB (publ), Annual General Meeting, Apr 27, 2023

Second quarter 2022 earnings released

Independent Chairman recently bought kr2.8m worth of stock

Medicover AB (publ) (OM:MCOV B) acquired Konzilijum.

Investor sentiment deteriorated over the past week

Medicover AB (publ) (OM:MCOV B) signed an agreement to acquire Übag Mvz Meindentist Gbr.

High number of new directors

Medicover AB (publ) (OM:MCOV B) acquired Kliniki Terapii Allenort Holding Sp. z o.o.

Independent Chairman recently bought kr3.3m worth of stock

Medicover AB (Publ) Elects Anne Berner and Azita Shariati as Board Members

Full year 2021 earnings released: EPS: €0.69 (vs €0.18 in FY 2020)

Insufficient new directors

Upcoming dividend of €0.12 per share

Full year 2021 earnings released: EPS: €0.69 (vs €0.18 in FY 2020)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

General Legal Counsel recently bought kr518k worth of stock

Now 24% undervalued after recent price drop

Medicover AB (publ) Proposes Dividend for the Financial Year 2021, Expected Payable on 6 May 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Medicover AB (publ) (OM:MCOV B) acquired an unknown majority stake in Mediplus Clinic.

Investor sentiment deteriorated over the past week

Chief Financial Officer recently sold kr1.4m worth of stock